Florida Cancer Specialists’ Research Presented at American Society of Clinical Oncology’s Annual Meeting
Clinical Trial Research at FCS in 26 Presentations, Including 19 from Phase 1 Clinical Trials Program
Fort Myers, FL – June 6, 2016.....Florida Cancer Specialists & Research Institute (FCS) announced that there were a record 26 presentations co-authored by FCS physicians that were presented at the 2016 American Society of Clinical Oncology (ASCO) annual meeting, held in Chicago, IL, June 3 – 7, 2016. The ASCO annual meeting is the largest gathering of oncologists in the world. This year’s theme is “Collective Wisdom: The Future of Patient-Centered Care and Research” and the meeting featured an address by Vice-President Joe Biden on the “Cancer Moonshot Initiative,” which was outlined in President Obama’s State of the Union address to Congress in January."
19 of the FCS co-authored presentations were from research done through the FCS Phase 1 Drug Development Unit (DDU) in Sarasota, FL, led by Dr. Manish Patel, Director of Drug Development Sarasota, and Dr. Judy Wang. Dr. Patel said, “A high percentage of the presentations from the DDU trials included early and senior authorships. It is particularly gratifying that the DDU has contributed so much to the body of knowledge about new cancer treatments. Our strong relationship with Sarah Cannon Research Institute is pivotal to this success.”
Additional FCS physician investigators included Drs. Patrick Acevedo, Ahmed Al-Hazzouri, Jennifer Cultrera ,Lowell Hart (FCS Scientific Director of Clinical Research), Maen Hussein, Vasundhara Iyengar, Michael McCleod, James Reeves, Pablo Reyes, Frank Rodriguez, Sandeep Thaper,Marays Veliz and Robert Whorf (FCS Director of Research Operations).
FCS CEO Brad Prechtl said, “As a statewide strategic partner of Sarah Cannon Research Institute, one of the leading clinical trial organizations in the world, Florida Cancer Specialists is dedicated to refining the science and the study of malignancies and sharing knowledge and new findings that will rapidly advance and improve cancer treatments for our patients. The fact that we had so many presentations accepted at ASCO is a reflection of the strong commitment to clinical research at FCS.”
Dr. William Harwin, Founder & President of FCS, added, “The research program at Florida Cancer Specialists rivals that of some academic medical centers. With the drug development unit in our network, there is a dedicated program of Phase 1 Clinical Trials that puts FCS on the cutting-edge of identifying newer targeted and immunotherapies that are changing the future of cancer treatment. In 2015, for example, 70% of all new cancer drugs were studied in clinical trials offered by FCS prior to FDA approval. This means that, as a community practice, we are able to bring these potentially life-saving advances to our patients in their own communities.”